Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06072183




Registration number
NCT06072183
Ethics application status
Date submitted
2/10/2023
Date registered
10/10/2023
Date last updated
26/07/2024

Titles & IDs
Public title
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
Scientific title
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Secondary ID [1] 0 0
2022-502518-98-00
Secondary ID [2] 0 0
B7981080
Universal Trial Number (UTN)
Trial acronym
Tranquillo 2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ritlecitinib
Treatment: Drugs - Ritlecitinib
Treatment: Drugs - Placebo

Experimental: Arm 1- Ritlecitinib 100 milligrams (mg) - Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

Experimental: Arm 2- Ritlecitinib 50mg - Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

Placebo comparator: Arm 3- Placebo - Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

Experimental: Arm 4- Ritlecitinib 100mg - Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks.


Treatment: Drugs: Ritlecitinib
100mg Capsule

Treatment: Drugs: Ritlecitinib
50mg Capsule

Treatment: Drugs: Placebo
Matching capsule
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52
Timepoint [1] 0 0
52 Weeks
Primary outcome [2] 0 0
Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52
Timepoint [2] 0 0
52 Weeks
Primary outcome [3] 0 0
Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation.
Timepoint [3] 0 0
Baseline through 108 weeks
Primary outcome [4] 0 0
Incidence of Clinically significant laboratory abnormalities.
Timepoint [4] 0 0
Baseline through 108 weeks
Secondary outcome [1] 0 0
Response based on F-VASI75 at 24 and 36 weeks
Timepoint [1] 0 0
24 and 36 Weeks
Secondary outcome [2] 0 0
US-Only: Response based on T-VASI50 at 24 and 36 weeks
Timepoint [2] 0 0
24 and 36 weeks
Secondary outcome [3] 0 0
Global (Other than US):Patient Global Impression of Severity-Face (PGIS-F)
Timepoint [3] 0 0
Week 24, 36 and week 52
Secondary outcome [4] 0 0
Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Timepoint [4] 0 0
Week 24, 36 and week 52
Secondary outcome [5] 0 0
Global (Other Than US): Response based on T-VASI50 at Week 24, 36 and 52
Timepoint [5] 0 0
Week 24, 36 and 52
Secondary outcome [6] 0 0
Patient Global Impression of Change-Face (PGIC-F)
Timepoint [6] 0 0
Week 36 and week 52
Secondary outcome [7] 0 0
Patient Global Impression of Change- Overall vitiligo(PGIC-V)
Timepoint [7] 0 0
Week 36 and week 52
Secondary outcome [8] 0 0
Change from baseline in Dermatology Life Quality Index (DLQI)
Timepoint [8] 0 0
Week 52
Secondary outcome [9] 0 0
Proportion of participants achieving disease stabilization
Timepoint [9] 0 0
Baseline through week 104
Secondary outcome [10] 0 0
Response based on T-VASI50
Timepoint [10] 0 0
Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
Secondary outcome [11] 0 0
Response based on F-VASI75
Timepoint [11] 0 0
Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
Secondary outcome [12] 0 0
Response based on T-VASI75
Timepoint [12] 0 0
Baseline through week 4, week 8, week 12, week 24, week 36, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
Secondary outcome [13] 0 0
Global (Other than US): Response based on T-VASI75
Timepoint [13] 0 0
Baseline through week 52
Secondary outcome [14] 0 0
Proportion of participants with sustained improvement in T-VASI
Timepoint [14] 0 0
Week 36 through week 52
Secondary outcome [15] 0 0
Proportion of participants with sustained improvement in F-VASI
Timepoint [15] 0 0
Week 36 through week 52
Secondary outcome [16] 0 0
Time to rescue medication use
Timepoint [16] 0 0
Baseline through week 104
Secondary outcome [17] 0 0
US-Only: Percentage change from baseline (% CFB) in F-VASI at Weeks 24, 36 and 52
Timepoint [17] 0 0
Weeks 24, 36 and 52
Secondary outcome [18] 0 0
US-Only: % CFB in T-VASI at weeks 24, 36 and 52
Timepoint [18] 0 0
Weeks 24, 36 and 52
Secondary outcome [19] 0 0
Response based on T-VASI90
Timepoint [19] 0 0
Baseline through week 52
Secondary outcome [20] 0 0
Response based on T-VASI100
Timepoint [20] 0 0
Baseline through week 52
Secondary outcome [21] 0 0
Response based on F-VASI50
Timepoint [21] 0 0
Baseline through week 104
Secondary outcome [22] 0 0
Change from baseline in the Hospital Anxiety and Depression Scale (HADS)
Timepoint [22] 0 0
Week 52
Secondary outcome [23] 0 0
The proportion of patients achieving absence of depression on HADS depression subscale
Timepoint [23] 0 0
Week 52
Secondary outcome [24] 0 0
The proportion of patients achieving absence of anxiety on HADS anxiety subscale
Timepoint [24] 0 0
Week 52
Secondary outcome [25] 0 0
US-Only: Patient Global Impression of Severity-Face (PGIS-F)
Timepoint [25] 0 0
Week 52
Secondary outcome [26] 0 0
US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Timepoint [26] 0 0
Week 52
Secondary outcome [27] 0 0
% CFB in F-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.
Timepoint [27] 0 0
Baseline through week 104
Secondary outcome [28] 0 0
% CFB in T-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.
Timepoint [28] 0 0
Baseline through week 104

Eligibility
Key inclusion criteria
1. Participants aged 18 years (or the minimum age of consent in accordance with local regulations) or older (no upper age limit) at Screening.

• Meeting reproductive criteria for female participants.

Disease Characteristics:
2. Eligible participants must have at both Screening and BL:

* A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and
* BSA involvement 4% to 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet and
* BSA =0.5% involvement on the face. Face is defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. Face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
* F-VASI =0.5 and T-VASI =3; and
* Either active or stable nonsegmental vitiligo at Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease.

Active vitiligo is defined as:

Participants will be classified as having active vitiligo based on the presence of at least one active lesion at BL defined as one of the following:
* New/extending lesions(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record);
* Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters;
* Trichrome lesion(s); Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin;
* Koebner phenomenon/phenomena (excluding Type 1 [history based on isomorphic reaction]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.

Stable vitiligo is defined as:

• Participants will be classified as having stable vitiligo based on an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) will be classified as having stable disease.

Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.
3. Additional inclusion criteria are:

* If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
* Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Medical Conditions:

1. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

• Any psychiatric condition including recent or active suicidal ideation or behavior that meets defined criteria.
2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:

* Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criteria (including but not limited to segmental vitiligo and mixed vitiligo).
* Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [minor manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
* Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or BL Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
* Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions or leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
* Have a superficial skin infection within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
3. General Infection History:

* Have a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
* Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.
* Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis.
4. Specific Viral Infection History:

* History (single episode) of disseminated HZ or disseminated herpes simplex or recurrent (more than one episode of) localized, dermatomal HZ.
* Infected with HBV or HCV: all participants will undergo screening for HBV and HBC for eligibility.
* Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.
* Have a known immunodeficiency disorder (including positive serology for HIV at screening) or a first-degree relative with a hereditary immunodeficiency.
5. Other Medical Conditions:

* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements.
* History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention.
* Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered current, fluctuating, or progressive.
* Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
* Abnormal findings on the Screening chest imaging (eg, chest x-ray). Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation.
* Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP.
* Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
* Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.

Prior/Concomitant Therapy:
6. Have received any of the prohibited treatment regimens specified.

Prior/Concurrent Clinical Study Experience:
7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 [Baseline] or within 5 half-lives, whichever is longer.

Diagnostic Assessments:

Any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:
8. Renal impairment
9. Hepatic dysfunction
10. Other laboratory abnormalities
11. Standard 12-lead ECG that demonstrates clinically relevant abnormalities

Other
12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
13. In South Africa only participants are excluded without one of the following:

* Document evidence form a health professional of having received varicella vaccination (two doses); or
* Evidence of prior exposure to VZV based on serological testing (ie a positive VZV IgG Ab result) at Screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
14/07/2027
Actual
Sample size
Target
1450
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Dr Rodney Sinclair Pty Ltd - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sofia
Country [22] 0 0
Canada
State/province [22] 0 0
Manitoba
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
Canada
State/province [25] 0 0
Saskatchewan
Country [26] 0 0
China
State/province [26] 0 0
Beijing
Country [27] 0 0
China
State/province [27] 0 0
Fujian
Country [28] 0 0
China
State/province [28] 0 0
Guangdong
Country [29] 0 0
China
State/province [29] 0 0
Guizhou
Country [30] 0 0
China
State/province [30] 0 0
Hebei
Country [31] 0 0
China
State/province [31] 0 0
Henan
Country [32] 0 0
China
State/province [32] 0 0
Hubei
Country [33] 0 0
China
State/province [33] 0 0
Hunan
Country [34] 0 0
China
State/province [34] 0 0
Inner Mongolia
Country [35] 0 0
China
State/province [35] 0 0
Jiangsu
Country [36] 0 0
China
State/province [36] 0 0
Jilin
Country [37] 0 0
China
State/province [37] 0 0
Shaanxi
Country [38] 0 0
China
State/province [38] 0 0
Shanghai
Country [39] 0 0
China
State/province [39] 0 0
Sichuan
Country [40] 0 0
China
State/province [40] 0 0
Tianjin
Country [41] 0 0
China
State/province [41] 0 0
Yunnan Sheng
Country [42] 0 0
China
State/province [42] 0 0
Zhejiang
Country [43] 0 0
China
State/province [43] 0 0
Fuzhou
Country [44] 0 0
China
State/province [44] 0 0
Shijiazhuang
Country [45] 0 0
Germany
State/province [45] 0 0
Nordrhein-westfalen
Country [46] 0 0
Germany
State/province [46] 0 0
Rheinland-pfalz
Country [47] 0 0
Germany
State/province [47] 0 0
Sachsen-anhalt
Country [48] 0 0
Germany
State/province [48] 0 0
Sachsen
Country [49] 0 0
Hungary
State/province [49] 0 0
Baranya
Country [50] 0 0
Hungary
State/province [50] 0 0
Békés
Country [51] 0 0
Hungary
State/province [51] 0 0
Csongrád
Country [52] 0 0
Hungary
State/province [52] 0 0
Jász-nagykun-szolnok
Country [53] 0 0
Hungary
State/province [53] 0 0
Budapest
Country [54] 0 0
Hungary
State/province [54] 0 0
Debrecen
Country [55] 0 0
Hungary
State/province [55] 0 0
Kaposvár
Country [56] 0 0
Italy
State/province [56] 0 0
Roma
Country [57] 0 0
Japan
State/province [57] 0 0
Aichi
Country [58] 0 0
Japan
State/province [58] 0 0
Chiba
Country [59] 0 0
Japan
State/province [59] 0 0
Hyogo
Country [60] 0 0
Japan
State/province [60] 0 0
Ibaraki
Country [61] 0 0
Japan
State/province [61] 0 0
Nara
Country [62] 0 0
Japan
State/province [62] 0 0
Osaka
Country [63] 0 0
Japan
State/province [63] 0 0
Shizuoka
Country [64] 0 0
Japan
State/province [64] 0 0
Tokyo
Country [65] 0 0
Japan
State/province [65] 0 0
Yamaguchi
Country [66] 0 0
Poland
State/province [66] 0 0
Dolnoslaskie
Country [67] 0 0
Poland
State/province [67] 0 0
Kujawsko-pomorskie
Country [68] 0 0
Poland
State/province [68] 0 0
Mazowieckie
Country [69] 0 0
Poland
State/province [69] 0 0
Malopolskie
Country [70] 0 0
Poland
State/province [70] 0 0
Podlaskie
Country [71] 0 0
Poland
State/province [71] 0 0
Lódzkie
Country [72] 0 0
Poland
State/province [72] 0 0
Slaskie
Country [73] 0 0
Slovakia
State/province [73] 0 0
Banskobystrický KRAJ
Country [74] 0 0
Slovakia
State/province [74] 0 0
Prešovský KRAJ
Country [75] 0 0
Slovakia
State/province [75] 0 0
Trnavský KRAJ
Country [76] 0 0
Slovakia
State/province [76] 0 0
Bratislava
Country [77] 0 0
Slovakia
State/province [77] 0 0
Kosice
Country [78] 0 0
Spain
State/province [78] 0 0
Barcelona [barcelona]
Country [79] 0 0
Spain
State/province [79] 0 0
Catalunya [cataluña]
Country [80] 0 0
Spain
State/province [80] 0 0
Galicia [galicia]
Country [81] 0 0
Spain
State/province [81] 0 0
Madrid, Comunidad DE
Country [82] 0 0
Spain
State/province [82] 0 0
Madrid
Country [83] 0 0
Spain
State/province [83] 0 0
Santiago de Compostela
Country [84] 0 0
Spain
State/province [84] 0 0
València
Country [85] 0 0
Spain
State/province [85] 0 0
Zaragoza
Country [86] 0 0
Taiwan
State/province [86] 0 0
Kaohsiung
Country [87] 0 0
Taiwan
State/province [87] 0 0
Taipei
Country [88] 0 0
Taiwan
State/province [88] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06072183